News – VivaZome Therapeutics

Latest news and media releases

Craig Newton
May 24, 2022
12:26 pm
0 comments

VivaZome to collaborate with UQ Traumatic Brain Injury experts to develop exosome-based therapies

VivaZome Therapeutics Pty Ltd has entered into a Memorandum of Understanding (MoU) with The University of Queensland (UQ) focussing on improved therapies for Traumatic Brain Injury (TBI) and post-traumatic epileptogenesis (PTE). TBI afflicts close to 69 million people globally. Under the MoU, VivaZome will collaborate with Professor David Reutens – Director of the Centre for […]

Craig Newton
February 2, 2022
11:11 am
0 comments

VivaZome wins Cytiva ANZ BioChallenge 2022

VivaZome Therapeutics has been awarded the top prize in the 2022 Cytiva BioChallenge for the Australia and NewZealand region. The prize, valued at approximately AUD $200,000, will further assist VivaZome in its quest to develop off-the-shelf regenerative medicines. Part of Cytiva’s BioChallenge global series, the inaugural challenge for the ANZ region received 32 applications from […]

Craig Newton
January 27, 2022
1:25 pm
0 comments

VivaZome to collaborate with ANU retinal disease experts to develop exosome-based therapies

VivaZome Therapeutics Pty Ltd is delighted to be collaborating with researchers at the Australian National University (ANU) and other expert groups focussing on improved therapies for age-related macular degeneration (AMD). The project entitled “The use of extracellular vesicles (EVs) for therapeutic RNA delivery as a novel treatment for retinal degenerations” is supported by a grant […]

Craig Newton
May 25, 2021
12:09 pm
0 comments

VivaZome and ReNerve to collaborate on nerve repair

ReNerve and VivaZome have entered a collaboration to combine their leading scaffold and exosome technologies, skills and experience to explore new solutions for the repair of spinal cord injuries. The two companies will work together to explore the potential of combining the ReNerve NervAlign® nerve cuff with VivaZome’s proprietary exosomes to enhance nerve regrowth in […]

Craig Newton
May 11, 2021
2:05 pm
0 comments

VivaZome presents at 2021 American Society of Gene & Cell Therapy conference

Viva Zome CEO David Haylock is presenting at the Annual Conference of the American Society of Gene and Cell Therapy on 13 May 2021 in an Industrial Symposium sponsored by Pall Corporation. His presentation is entitled “Exosome manufacture in a fixed-bed bioreactor, and overcoming production challenges” Read more at http://vivazome.com/wp-content/uploads/2021/05/VivaZome-ASGCT-release-11-May-2021.pdf

Craig Newton
February 16, 2021
4:47 pm
0 comments

VivaZome and La Trobe University enter new research collaboration to develop exosome therapeutics

VivaZome Therapeutics Pty Ltd and La Trobe University today announced that they have entered into a new collaborative research project focussed on developing novel exosome therapeutics. Under the collaborative arrangement, VivaZome scientists will work alongside members of Professor Andrew Hill’s laboratory in the La Trobe Institute for Molecular Science (LIMS). Professor Hill is one of […]

Craig Newton
December 21, 2020
11:38 am
0 comments

VivaZome and BIA Separations collaborate; VivaZome CEO presents at 2021 Biotech Showcase

BIA’s unique CIM (Convective Interaction Media) monolith chromatography technology will be used to purify exosomes from VivaZome’s cell cultures, with the aim of developing a high-efficiency downstream purification and concentration process for exosome production. Click to read full media release. http://vivazome.com/wp-content/uploads/2021/01/VivaZome-BIA-release-21-Dec-2020.pdf

Craig Newton
November 22, 2020
1:14 pm
0 comments

Exosome Therapeutics: Academic Curiosity or Commercial Reality

VivaZome features in lead article in International BioPharmaceutical Industry journal. “Exosome Therapeutics: Academic Curiosity or Commercial Reality” written by VivaZome CEO David Haylock and key academic collaborator Prof Andy Hill (La Trobe Uni). Click here to read article: 2020-IBI_Summer-Vivazome

Craig Newton
June 26, 2020
5:46 pm
0 comments

VivaZome in the spotlight as Precinct Partner at La Trobe University

VivaZome’s David Haylock says his company’s decision to base themselves in the Research & Innovation Precinct at La Trobe University revolved largely around one key researcher. Read the full story here https://www.latrobe.edu.au/industry-and-community/industry-partner-of-choice/research-and-innovation-precinct/precinct-partner-spotlight/vivazome

Craig Newton
June 20, 2020
5:54 pm
0 comments

VivaZome features in “Inspire”

VivaZome features in “Inspire” – Research Australia’s Showcase for Health and Medical Research and Innovation. Download the article here: INSPIRE_20Jun2020

Craig Newton
May 21, 2020
9:00 am
0 comments

VivaZome and Cytiva to collaborate on downstream technology for exosome purification

Under the agreement, VivaZome will provide substantial quantities of exosome-rich, cell culture supernatant produced by VivaZome’s preferred cell type. Cytiva’s Next Generation Resins Team, located in Uppsala in Sweden, will use the VivaZome material to evaluate Cytiva chromatography resins and fibre materials for their potential to separate and concentrate exosomes, with an emphasis on demonstrating […]

Craig Newton
May 5, 2020
9:00 am
0 comments

VivaZome licenses University of Adelaide stem cell technology

Under the Licence Agreement, VivaZome has secured world-wide rights to intellectual property for the selection, isolation, purification, expansion and processing of stem cells from certain human tissues suitable for production of subcellular fractions. VivaZome will process these fractions to generate exosome products. Read full media release here

Craig Newton
April 22, 2020
9:00 am
0 comments

VivaZome and Toolgen extend collaboration based on successful proof-of-concept

Under the pilot study, ToolGen undertook a knock-down gene editing using its CRISPR/Cas9 technology, with the gene and the cell specified by VivaZome. The gene editing was successfully accomplished and exosome production by the edited cells was maintained at high levels.The nest aim to create a gene-edited cell that could be used in VivaZome’s exosome […]

Craig Newton
November 8, 2019
9:00 am
0 comments

Sienna and VivaZome to evaluate EXO-NET for VivaZome’s exosome-based therapeutics

Sienna has entered into an agreement with VivaZome to assist in the development of a commercial and scalable purification process for VivaZome’s exosome-based therapies. This will be the first potential therapeutic application of Sienna’s capture technology, EXO-NET. Sienna will provide EXO-NET beads which rapidly and specifically capture exosomes, potentially enabling the development of a commercial […]

Craig Newton
October 30, 2019
9:00 am
0 comments

VivaZome appoints David Haylock PhD as CEO

Dr Haylock joined the Company as Chief Scientific Officer (CSO) in July, 2019. In his role as CEO, Dr Haylock will maintain his CSO function. Previously Dr Haylock has held senior leadership and management roles iat CSIRO, the Australian Stem Cell Centre, the Peter MacCallum Cancer Centre and the Institute for Medical and Veterinary Sciences. […]

Craig Newton
April 27, 2019
9:00 am
0 comments

VivaZome and ToolGen to collaborate on gene editing for enhanced exosome production

Under the agreement, ToolGen will use its CRISPR/Cas9 technology to introduce gene edits into selected cell types to selectively altering the content and characteristics of exosomes produced by the cells.The agreement includes an option for VivaZome to license ToolGen’s technology, as well as any IP arising from the research program. Read full media release here

Craig Newton
December 18, 2017
9:00 am
0 comments

VivaZome awarded $2.18m grant for exosome therapy development

VivaZome Therapeutics has been awarded an Australian Government CRC-P grant of $2.18m in support of the project “Enabling Exosome Therapy: Developing an Advanced Manufacturing Process”, with the funds provided under the Advanced Manufacturing Scheme. Joining VivaZome in the CRC-P are La Trobe University and SeerPharma Pty Ltd, each of which bring high-level scientific and operational […]